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Micro-abstract: In a Phase I dose-finding study of metronomic daily oral vinorelbine in 
advanced non-small-cell lung cancer, a recommended dose was established for this thera-
peutic approach. In addition, this trial revealed promising efficacy data and an acceptable 
tolerability profile. The observed vinorelbine blood concentrations suggest continuous anti-
angiogenic coverage.
Introduction: We present a Phase I dose-finding study investigating metronomic daily oral 
vinorelbine (Navelbine® Oral, NVBo) in advanced non-small-cell lung cancer (NSCLC).
Patients and methods: Patients with stage III/IV NSCLC received daily NVBo at fixed dose 
levels of 20–50 mg/d for 21 days of each 4-week cycle. Primary end point was the maximum 
tolerated dose. Secondary end points included tumor response, time to progression (TTP), 
overall survival (OS) and tolerability.
Results: Twenty-seven patients with advanced NSCLC were enrolled. Most of them were 
extensively pretreated. Daily NVBo was well tolerated up to 30 mg/d. At 40 mg/d, two of 
five patients experienced dose-limiting toxicities (DLTs). Three of six patients had DLTs at 
the 50 mg/d level. The recommended dose was established at 30 mg/d in cycle 1, with escala-
tion to 40 mg/d in cycle 2, if tolerated. Pharmacokinetic analyses showed continuous blood 
exposure over 21 days and only marginal accumulation. The tolerability profile was acceptable 
(all dose levels – all grades: decreased appetite 33%, diarrhea 33%, leukopenia 33%, nausea 
30%, vomiting 26%; $grade 3: leukopenia 30%, lymphopenia 19%, neutropenia 19%, febrile 
neutropenia 15%). Disease control rate, OS and TTP signaled a treatment effect.
Conclusion: Daily metronomic NVBo therapy in extensively pretreated patients with advanced 
NSCLC is feasible and safe at the recommended dose of 30 mg/d. Escalation to 40 mg/d in 
the second cycle is possible. The blood concentrations of vinorelbine after daily metronomic 
dosing reached lower peaks than intravenous or oral conventional dosing. Blood concentra-
tions were consistent with anti-angiogenic or immune modulating pharmacologic properties 
of vinorelbine. Further studies are warranted to evaluate the safety and efficacy of this novel 
approach in specific patient populations.
Keywords: NSCLC, dose escalation, lung carcinoma, vinca-alkaloid, anti-angiogenic treatment, 
cytotoxic therapy, vinorelbine capsules
Introduction
Lung cancer remains a major burden to patients and their communities. With 1.8 million 
new cases and 1.59 million deaths in 2012, lung cancer is one of the most common, 
and most fatal, cancers worldwide.1,2
Non-small-cell lung cancer (NSCLC) accounts for .80% of lung cancer cases. 
Although patients with early-stage disease may be cured by surgical resection, most 
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patients with NSCLC present with advanced, inoperable 
disease. These patients, in particular those whose tumors do 
not respond to treatment, have a poor prognosis.3,4
Vinorelbine, a semisynthetic vinca-alkaloid, has dem-
onstrated a good safety profile and consistent treatment 
efficacy across randomized trials in advanced NSCLC.5–9 
The combination of cisplatin and vinorelbine is considered 
a standard of care in this setting.10–12
Most cytotoxic chemotherapy treatments are admin-
istered intravenously (iv). In NSCLC, single doses of iv 
chemotherapeutics are often administered on the first day 
of each 3- or 4-week cycle or more frequently, for example, 
on a weekly basis.
However, as the availability of oral cancer treatments 
increases,13 potential advantages of this form of dosing are 
becoming clear. In addition to eliminating the discomfort, 
stress and potential complications associated with iv lines,14 
oral treatments can be administered at home, increasing con-
venience for patients and reducing the costs associated with 
visits to chemotherapy clinics.15,16 Oral treatments may be 
administered frequently without the burden associated with 
repeated infusions or continuous chemotherapy pumps.
Metronomic low-dosing schedules made possible by 
oral formulations may have biologic advantages compared 
to conventional chemotherapy boluses. The pharmacokinet-
ics (PK) of metronomic administration allow for constant 
exposure to the cytotoxic agent, which may prevent tumor 
regrowth that may otherwise happen between conventional 
chemotherapy cycles. Furthermore, the toxic effects of 
chemotherapy might be lessened due to lower peak plasma 
concentrations. In addition, metronomic chemotherapy has 
been described to mediate antitumor effects by mechanisms 
other than cytotoxicity. The frequent administration of low-
dose chemotherapy can induce anti-angiogenic effects, target 
tumor vasculature and strengthen the antitumor immune 
response by suppressing regulatory T cells and inducing 
the maturation of dendritic cells.17,18 Metronomic treatment 
strategies in various tumor entities were recently reviewed 
by Bocci and Kerbel19 in Nature Reviews. These authors 
emphasized the importance of including PK data in studies 
of metronomic chemotherapy in order to better understand 
dosing and treatment effects.
Oral vinorelbine (Navelbine® soft capsules; Pierre Fabre 
Médicament, Boulogne Billancourt, France; NVBo) has 
similar cytotoxic activity to iv vinorelbine.20–22 Initially, mim-
icking iv regimens, NVBo was given weekly23,24; however, 
taking advantage of the oral formulation, more frequent and 
metronomic dosing has been recently introduced. Previous 
studies have shown that the administration of NVBo three 
times per week is feasible and well tolerated.25,26 Preliminary 
data indicate that fractionated doses of 70 mg/m2/wk split 
over days 1, 3 and 5 as well as fixed doses of up to 60 mg 
every other day are well tolerated and show activity in some 
patients.27,28
In this Phase I clinical trial, tolerability and preliminary 
efficacy of a metronomic treatment schedule, using fixed 
daily doses of 20–50 mg NVBo administered for 21 consecu-
tive days of a 28-day cycle, were investigated in extensively 
pretreated patients with advanced NSCLC.
Patients and methods
study design and objectives
This open-label Phase I clinical study recruited patients from 
April 2007 to December 2011. The primary objective was 
to determine the maximum tolerated dose (MTD) of daily 
NVBo. Secondary end points included tumor response, time 
to progression (TTP), overall survival (OS), tolerability pro-
file and pharmacokinetic parameters. Adverse events (AEs) 
were graded according to Common Terminology Criteria for 
Adverse Events v3.0.29.29
Patients and study centers
Eligible patients were at least 18 years old and had his-
tologically or cytologically confirmed stage IIIB/IV NSCLC 
(TNM 6) or recurrent disease after local therapy, with an indi-
cation for palliative chemotherapy. Both previously untreated 
patients and those who had received treatment with one or 
more lines of systemic therapy were eligible for inclusion. 
Patients were eligible if they had at least one measurable lesion 
(Response Evaluation Criteria in Solid Tumors [RECIST] 
v1.030), a Karnofsky index of at least 70%, a life expectancy 
of at least 12 weeks and adequate organ function.
Patients were excluded if they had metastases of the 
central nervous system, superior vena cava syndrome, 
symptomatic sensory neuropathy greater than grade 1 or 
any concomitant uncontrolled medical disorder. Moreover, 
patients could not have received previous treatment with 
vinorelbine and were required to be off systemic treatments 
and radiation for 30 days prior to enrollment. The study was 
conducted in four German centers.
Treatment
The patients were treated at four dose levels: 20, 30, 40 
and 50 mg/d NVBo administered as levels I, II, III and IV, 
respectively. One treatment cycle was defined as a 28-day 
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Metronomic treatment of advanced non-small-cell lung cancer
a 7-day treatment-free interval. This schedule was selected 
to limit potential accumulation and associated toxicity.
In the dose escalation phase of the study, a 3+3 dose 
escalation design was applied. Three to six patients were 
treated at each dose level before escalation to the next dose 
level. The MTD was defined at the dose level, where at 
least two of six patients experienced dose-limiting toxicities 
(DLTs); the level below the MTD was defined as recom-
mended dose for further evaluation. DLTs were assessed 
during cycle 1 at dose levels I–III. At dose level IV, the 
study was amended in order to include cycles 1 and 2 in 
the DLT assessment based on events fulfilling DLT criteria 
observed in cycle 2. DLTs were defined as follows: fever 
(with or without clinical infection), three elevations of oral 
temperature to .38°C during a 24-hour period or a single 
elevation in oral temperature to .38.5°C concomitant with 
grade 4 neutropenia and requiring iv antibiotics and/or 
hospitalization; grade 4 neutropenia and/or grade 2 throm-
bocytopenia lasting for $7 days; grade 4 or symptomatic 
grade 3 thrombocytopenia and any non-hematological event 
higher than grade 2 (excluding nausea/vomiting and AEs 
considered unrelated to treatment).
After MTD identification, it was planned to enroll a 
maximum of 12 patients at the recommended dose level. 
Due to slow accrual, only seven patients were included at 
this level.
PK assessment
Vinorelbine blood levels were assessed on days 1 and 21 of 
cycle 1, with additional trough levels on days 8 and 15. Blood 
concentrations of vinorelbine and its only active metabolite 
4-O-deacetylvinorelbine (DVRL) were quantified using a 
fully validated liquid chromatography–tandem mass spec-
trometry with a lower limit of quantification of 0.25 ng/mL. 
PK parameters, such as the area under the plasma drug–
concentration time curve (AUC), were calculated by a model-
independent approach using KINETICA® software (Thermo 
Fischer Scientific Inc., Waltham, MA, USA). Median AUC 
estimates were used to calculate the accumulation ratio based 
on exposure (R
AUC
). The accumulation ratios based on trough 





Standard imaging was performed after every second cycle. 
Assessments of tumor response were performed according 
to RECIST v1.0. After treatment discontinuation, patients 
were followed up every 3 months until death.
statistics
Data were evaluated using SAS® version 9.2 (Cary, NC, 
USA). Standard descriptive methods were used for all cor-
responding data. Time-to-event parameters were analyzed 
using the Kaplan–Meier method.
Duration of disease control (DoDC) was measured from 
the start of treatment until progression or death in patients with 
response or stable disease. TTP was calculated from the start 
of treatment until progression. If progression or death did not 
occur during treatment or within 30 days after treatment termi-
nation, patients were censored with the date of the last tumor 
assessment. Survival was measured from the start of treatment 
until death. Patients who were alive or lost to follow-up were 
censored with the last date they were known to be alive.
ethical principles
All patients provided written informed consent. Approval of 
the study was obtained from the responsible ethics commit-
tee (ethics committee of the Medical Department Ludwig-
Maximilians-University Munich) and regulatory authority 
(Bundesinstitut für Arzneimittel und Medizinprodukte). The 
study was conducted in accordance with the Declaration of 




Twenty-seven patients were enrolled in the study; all patients 
received study treatment. The safety population (SAF) 
included all 27 patients and was identical with the intent-
to-treat population (ITT). In addition, the following popula-
tions were analyzed: patients evaluable for response (RESP; 
21 patients), patients evaluable for MTD (17 patients) and 
patients treated at the recommended dose level (RD; seven 
patients). The study population is summarized in a Consort 
diagram (Figure 1).
Baseline parameters and disease 
characteristics
Of the 27 enrolled patients, 55.6% were male. Patient age 
ranged between 49 and 78 years (median: 65 years). Most 
patients (63.0%) had a Karnofsky index of 70%–80%. The 
median time from the first NSCLC diagnosis until enrollment 
was 20.7 months (range: 0.4–78.5 months). The distribution of 
histology was 44.4% for squamous cell carcinoma and 55.6% 
for adenocarcinoma. A total of 22.2% and 77.8% of patients 
were classified as stages IIIB and IV at study entry, respec-
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liver metastases: additional baseline tumor locations included 
lymph nodes (40.7%), pleura (33.3%) and bone (18.5%). 
Nearly all patients had received prior chemotherapy (92.6%) 
mainly in palliative intention (77.8%); the median number of 
prior palliative treatment lines was 3 (range: 0–5). About half 
of the patients (51.9%) had prior radiotherapy. Demographic 
data and disease characteristics are shown in Table 1.
study treatment
The enrolled patients received a median of two treatment 
cycles (range: 1–33 cycles). The median treatment dura-
tion, absolute dose and relative dose intensity were 48 days 
(range: 3–912 days), 1,290 mg (range: 90–33,750 mg) and 
97.9% (range: 40.0%–105.8%), respectively. The main rea-
son for treatment discontinuation was progression or death 
(85.2%); discontinuations due to AEs occurred in 11.1% of 
the patients.
Maximum tolerated dose
A total of 17 patients were evaluable for MTD. Table 2 
provides a detailed overview on the dose escalation phase. 
At dose level III (40 mg/d), one of three patients expe-
rienced a DLT (neutropenia) in cycle 2, that is, after the 
protocol-specified DLT observation period. At dose level IV 
(50 mg/d), two of six patients showed DLTs during cycle 1 
(fever and neutropenia) and one patient experienced DLTs 
during cycle 2 (fever and non-hematological event). Accord-
ingly, the MTD was reached at dose level IV, and recruitment 
was extended at the draft recommended dose of 40 mg/d. 
However, one additional patient experienced a DLT during 
cycle 1 at this dose (fever).
Therefore, the following dose regimen was finally defined 
as recommended schedule for further assessment: 30 mg/d 
NVBo in cycle 1; escalation to 40 mg/d from cycle 2, if no 
DLT occurred during cycle 1. A total of seven patients were 
treated with this recommended schedule.
Pharmacokinetics
Cycle 1 PK could be assessed in a total of 21 patients. How-
ever, five of these patients were considered as non-evaluable 
on at least one of the PK days. Blood concentrations of 
vinorelbine generally increased with escalating dose levels. 
At 30 and 40 mg (Figure 2), the daily oral dosing of vinorel-
bine provided a continuous blood exposure, as median trough 
concentrations were all .1 ng/mL.
A marginal accumulation of vinorelbine was observed 
until day 8 based on residual concentrations (median R
Ctrough
 
ranged from 1.96 to 2.03 between day 1 and either day 8, 15 
or 21, all dose levels). This had no impact on global exposure 
over repeated dosing, as only minor differences in blood 
exposure were detected between days 1 and 21 (median 
R
AUC
 day 21/day 1: 0.8, 1.6, 1.8 and 0.7 at 20, 30, 40 and 
50 mg/d, respectively).
For DVRL, concentrations on day 1 were either not 
quantifiable or near the lower limit of quantitation for all 
patients. On day 21, DVRL concentrations were approximately 
or 1 ng/mL. As a result, no DVRL accumulation ratio could 
be calculated.
Tolerability
Of the 27 treated patients, 26 (96.3%) patients experienced at 






Figure 1 consort diagram.
Abbreviations: DlT, dose-limiting toxicity; iTT, intention-to-treat population; MTD, maximum tolerated dose population; rD, recommended dose population; 
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Metronomic treatment of advanced non-small-cell lung cancer
one event with potential relationship to NVBo (Table 3). 
The most frequently reported related events were decreased 
appetite (33.3%), diarrhea (33.3%), leukopenia (33.3%), 
nausea (29.6%) and vomiting (25.9%). The most frequently 
reported related AEs of grade 3 or higher were leukopenia 
(29.6%), lymphopenia (18.5%), neutropenia (18.5%) and 
febrile neutropenia (14.8%). In the RD population (n=7), 
the most frequently reported related events were decreased 
appetite (42.9%) and vomiting (28.6%).
Serious AEs were observed in 17 (63.0%) patients of 
the SAF, and in 8 (29.6%) of those patients, the event was 
rated as potentially related to NVBo. The latter included 
Table 1 Demographic data and disease characteristics
Characteristics ITT/SAF (n=27) RESP (n=21) MTD (n=17) RD (n=7)
gender
Male 15 (55.6%) 11 (52.4%) 10 (58.8%) 2 (28.6%)
Female 12 (44.4%) 10 (47.6%) 7 (41.2%) 5 (71.4%)
age (years)
Mean ± stD (median) 65±8 (65) 63±8 (64) 64±8 (64) 68±8 (69)
Body surface area (m2)
Mean ± stD (median) 1.9±0.3 (1.9) 1.9±0.3 (1.9) 1.8±0.2 (1.9) 1.8±0.2 (1.7)
Karnofsky index
70% 6 (22.2%) 3 (14.3%) 2 (11.8%) 3 (42.9%)
80% 11 (40.7%) 9 (42.9%) 8 (47.1%) 2 (28.6%)
90% 7 (25.9%) 6 (28.6%) 5 (29.4%) 1 (14.3%)
100% 3 (11.1%) 3 (14.3%) 2 (11.8%) 1 (14.3%)
smoking status
never 6 (22.2%) 5 (23.8%) 5 (29.4%) 1 (14.3%)
Former 8 (29.6%) 6 (28.6%) 4 (23.5%) 2 (28.6%)
current 7 (25.9%) 7 (33.3%) 5 (29.4%) 2 (28.6%)
Missing information 6 (22.2%) 3 (14.3%) 3 (17.6%) 2 (28.6%)
histology
squamous cell carcinoma 12 (44.4%) 11 (52.4%) 10 (58.8%) 1 (14.3%)
adeno carcinoma 13 (48.1%) 9 (42.9%) 6 (35.3%) 6 (85.7%)
adeno (bronchoalveolar) 2 (7.4%) 1 (4.8%) 1 (5.9%) 0
Tumor stage at study entry
iiiBa 6 (22.2%) 6 (28.6%) 6 (35.3%) 0
iV 21 (77.8%) 15 (71.4%) 11 (64.7%) 7 (100%)
Previous surgery for primary tumor 3 (11.1%) 2 (9.5%) 2 (11.8%) 1 (14.3%)
Prior chemotherapy 25 (92.6%) 20 (95.2%) 16 (94.1%) 7 (100%)
neoadjuvant 1 (3.7%) 1 (4.8%) 1 (5.9%) 0
adjuvant 3 (11.1%) 2 (9.5%) 1 (5.9%) 2 (28.6%)
curative 4 (14.8%) 4 (19.0%) 3 (17.6%) 0
Palliative 21 (77.8%) 17 (81.0%) 15 (88.2%) 5 (71.4%)
Prior palliative lines, median (range) 3 (0–5) 3 (0–5) 3 (0–5) 2 (1–3)
Prior radiation 14 (51.9%) 11 (52.4%) 9 (52.9%) 4 (57.1%)
Notes: Data were represented as n (% of patients). aOne of the patients had recurrence after local therapy.
Abbreviations: iTT, intention-to-treat population; MTD, maximum tolerated dose population; rD, recommended dose population; resP, response population; saF, safety 
population; stD, standard deviation.
Table 2 Dose escalation – DlTs observed during the dose escalation phase of the trial including toxicities observed at the MTD
















level i (20 mg/d) 3 0 – – – – –
level ii (30 mg/d) 3 0 – – – – –
level iii (40 mg/d) 3 1 2 (n=1)a – 1 – –
level iV (50 mg/d) = MTD 6 3 1 (n=2), 2 (n=1) 3 1 – 1
Draft rD (40 mg/d)b 2 1 1 (n=1) 1 – – –
Notes: Based on these results, the extension phase was initiated with a recommended dose of 30 mg vinorelbine/d and the option to increase to 40 mg/d in individual 
patients. aat that time, only cycle 1 was taken into account for DlT assessment; the study design was amended from level iV taking now into account cycles 1 and 2. 
bafter recruitment of two further patients at this draft rD level, one patient experienced a DlT during cycle 1. earlier, on the same dose (see level iii) another patient had 
experienced a DLT during cycle 2. As a total of two of five patients had experienced DLTs at 40 mg/d, it was concluded that the final recommended dose level should range 
between 30 and 40 mg, rather than to follow a strict 40 mg dose.
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the following cases: at dose level II (30 mg/d), one patient 
experienced grade 3 anorexia. At level III (40 mg/d), one 
patient experienced grade 4 febrile neutropenia and another 
patient grade 3 nausea. At level IV (50 mg/d), one patient 
experienced grade 4 leukopenia and grade 4 febrile neutro-
penia, one patient grade 4 neutropenic sepsis and another 
patient grade 4 leukopenia. At the recommended dose level 
(30–40 mg/d), one patient showed grade 2 vomiting and 
another patient experienced grade 4 febrile neutropenia, 
grade 4 pneumonia, grade 4 sepsis and grade 5 colitis. The 
latter patient was 74 years old, had several comorbidities 
(including hypertension, coronary heart disease and pulmo-
nary embolism), was extensively pretreated (adenocarcinoma 
stage IV, two prior treatments with pemetrexed plus cisplatin 
followed by erlotinib) and experienced these events at the 
end of cycle 2 (40 mg/d). The management of this case was 
further complicated by the patients’ delayed reporting of the 
early symptoms and initial refusal to be admitted for treat-
ment, so that treatment could not be delivered effectively.
Efficacy
In this heavily pretreated population, none of the patients 
experienced complete or partial response (Table 4). Four 
patients showed stable disease during the study, result-
ing in a disease control rate (DCR) of 19.0% in the RESP 
population (n=21). Kaplan–Meier analysis revealed a median 
DoDC of 8.7 months (95% confidence interval [95% CI]: 
4.9–27.3 months) in the patients with stable disease.
In the intent-to-treat population (n=27), the median 
TTP and OS were 1.7 months (95% CI: 1.4–2.1 months) and 
5.7 months (95% CI: 3.5–9.6 months), respectively.
Discussion
Metronomic chemotherapy is characterized by continuous 
long-term administration of chemotherapeutics at relatively 
low doses.17 Potential advantages of this form of dosing 
include lower toxicity, avoidance of drug resistance and 
anti-angiogenic effects.18,31 In recent years, preclinical and 
Figure 2 Vinorelbine blood concentrations on day 1 and day 21 (cycle 1) after daily dosing of oral vinorelbine.
Abbreviations: d, day; h, hours.
Table 3 aes potentially related to vinorelbine occurring in at 
least 10% of the saF and/or rD population
AE,  
n (% patients)
SAF (n=27) RD (n=7)
Any grade $Grade 3 Any grade $Grade 3
any event 20 (74.1%) 11 (40.7%) 3 (42.9%) 2 (28.6%)
hematological events
leukopenia 9 (33.3%) 8 (29.6%) 1 (14.3%) 1 (14.3%)
lymphopenia 6 (22.2%) 5 (18.5%) 1 (14.3%) 1 (14.3%)
neutropenia 5 (18.5%) 5 (18.5%) 1 (14.3%) 1 (14.3%)
Febrile 
neutropenia




9 (33.3%) 0 3 (42.9%) 0
Diarrhea 9 (33.3%) 0 1 (14.3%) 0
nausea 8 (29.6%) 1 (3.7%) 1 (14.3%) 0
Vomiting 7 (25.9%) 0 2 (28.6%) 0
Fatigue 5 (18.5%) 1 (3.7%) 1 (14.3%) 0
Dizziness 4 (14.8%) 0 0 0
asthenia 3 (11.1%) 0 1 (14.3%) 0
constipation 3 (11.1%) 0 0 0
Weight 
decreased
3 (11.1%) 0 0 0
colitis 1 (3.7%) 1 (3.7%) 1 (14.3%) 1 (14.3%)
Pneumonia 1 (3.7%) 1 (3.7%) 1 (14.3%) 1 (14.3%)
sepsis 1 (3.7%) 1 (3.7%) 1 (14.3%) 1 (14.3%)
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Metronomic treatment of advanced non-small-cell lung cancer
higher C
max
 and larger peak/trough fluctuations of circulating 
concentrations.35,36
Because vinorelbine is predominantly metabolized by 
hepatic CYP3A4,37 drug exposure may be higher in patients 
with impaired liver function. Patients with significantly 
impaired liver function were excluded from this study. This 
study included many patients who had undergone one or more 
lines of systemic chemotherapy. Although this population is 
clinically relevant, the MTD established in this setting may be 
lower than in a treatment-naive, first-line population. Careful 
investigation of the safety and efficacy in specific populations 
and treatment situations is required in future studies.
As this study was not primarily designed to assess efficacy 
of the tested treatment, efficacy results must be interpreted 
with caution, especially taking into account the extensive 
and mixed pretreatment of the included patient population. 
Considering these limitations, the observed results – with a 
DCR of 19.0%, a median TTP of 1.7 months and a median 
OS of 5.7 months – provide an initial signal with regard to 
clinical activity of the investigated regimen. The observed 
disease stabilization and lack of partial or complete responses 
in this study should be interpreted with consideration of the 
heavy pretreatment of most patients included. A retrospective 
analysis of third-line chemotherapy by Girard et al38 described 
a response rate of 38% after first-line treatment but only 14% 
and 6% after second- and third-line treatments, respectively. 
In contrast, the rate of disease stabilization following third-
line treatment was 30% and cancer-related symptoms and 
performance status improved during third-line treatment for 
many patients. A decreasing response rate with increasing 
number of lines of treatment was also reported in the large 
retrospective study by Massarelli et al,39 who showed third-
line response rates of only 2.3% and fourth-line response 
rates of 0% in contrast to first-line response rates over 20%. 
These results demonstrate that a low response rate is often 
seen following the administration of treatments in third or 
later line and should not in itself discourage further trials of 
a treatment. In this study, there was significant heterogene-
ity in the responses observed, as shown by the wide 95% CI 
for DCR (4.9–27.3 months), with some patients benefiting 
with .2 years of stable disease control. Molecular and clini-
cal predictors of response to metronomic vinorelbine have 
yet to be established. Future clinical trials of metronomic 
vinorelbine should include the search for potential predictors 
of response in clearly defined patient populations.
Several other recent trials have investigated and further 
ongoing trials are currently evaluating the metronomic 
application of NVBo in solid tumors. In a recent Phase I–II 
Table 4 Efficacy parameters







cr 0 0 0
Pr 0 0 0
sD 4 (14.8%) 4 (19.0%) 1 (14.3%)
PD 17 (63.0%) 17 (81.0%) 3 (42.9%)
not evaluable 6 (22.2%) 0 3 (42.9%)
Orr (cr + Pr) 0 0 0
Dcr (cr + Pr + sD) 4 (14.8%) 4 (19.0%) 1 (14.3%)
TTP
Patients with events 20 (74.1%) 20 (95.2%) 3 (42.9%)
TTP (median 
months)a (95% ci)a
1.7 (1.4–2.1) 1.7 (1.4–2.1) 1.3 (0.7–nr)
Os
Patients with events 26 (96.3%) 7 (100%)
Os (median months)a 
(95% ci)a
5.7 (3.5–9.6) na 3.9 (1.8–9.6)
Note: aKaplan–Meier analysis.
Abbreviations: CI, confidence interval; CR, complete response; DCR, disease 
control rate; iTT, intention-to-treat population; na, not analyzed; nr, not reached; 
Orr, overall response rate; Os, overall survival; PD, progressive disease; Pr, partial 
response; rD, recommended dose population; recisT, response evaluation criteria 
in solid Tumors; resP, response population; saF, safety population; sD, stable 
disease; TTP, time to progression.
clinical studies have investigated metronomic schedules 
using a variety of anti-neoplastic treatments including 
vinorelbine, cyclophosphamide, capecitabine, methotrexate, 
sorafenib, everolimus and temozolomide.31 However, con-
flicting results demonstrated the need for optimized patient 
selection and stratification.
This Phase I trial confirmed that NVBo can be 
admini stered safely on a daily basis with only marginal 
PK accumulation. In a “three weeks on, one week off” 
schedule, the recommended dose was found to be 30 mg/d 
in cycle 1 with escalation to 40 mg/d from cycle 2, if 
tolerated. The results show acceptable tolerability and 
only marginal PK accumulation. Moreover, the observed 
vinorelbine blood concentrations at 30 and 40 mg/d are in 
the 1–10 ng/mL range .24 hours, which suggests that a 
continuous anti-angiogenic coverage is maintained using 
this dose regimens.25 This vinorelbine concentration range is 
also consistent with the previously demonstrated effect of 
vinorelbine with platinum to sensitize tumor cells to cytotoxic 
T lymphocyte-mediated lysis.32 More broadly, while sparing 
the cytotoxic T cells, vinorelbine daily metronomic admin-
istration may continuously stimulate the maturation of 
dendritic cells and kill the immunosuppressive Treg cells, as 
was described for related chemotherapeutic agents.33,34 On the 
contrary, those effects may be triggered only episodically 
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study of metronomic NVBo plus capecitabine in patients with 
metastatic breast cancer, the MTD for NVBo was found to 
be 40 mg three times per week, combined with capecitabine 
500 mg three times per day from days 1–14 of a 21-day cycle. 
Initial efficacy data revealed a clinical benefit in 58.1% of the 
patients.26 In addition, Briasoulis et al25 investigated a metro-
nomic NVBo monotherapy in patients with various advanced 
solid tumors and suggested a NVBo dose of 50 mg given three 
times per week. This schedule was further investigated as first-
line and salvage treatment in NSCLC by Camerini et al,40 who 
demonstrated a clinical benefit in 58.1% of patients treated 
in first line, with a median TTP and OS of 5 and 9 months, 
respectively. As salvage treatment, this regimen showed a 
median TTP and OS of 2.2 and 9.4 months, respectively.41 
An adequate tolerability profile was observed in all of these 
studies. Subsequent Phase II studies investigating the three 
times per week as well as the continuous daily administra-
tion of metronomic NVBo in patients with metastatic breast 
cancer and advanced NSCLC are currently ongoing (EudraCT 
2014-003860-19, EudraCT 2014-003859-61, NCT03007992). 
The exclusion of the chemotherapy-free week in these regi-
mens may provide more continuous anti-neoplastic activity 
and offer additional biological benefit.
Conclusion
The results from this Phase I study in mostly extensively 
pretreated patients with advanced NSCLC show that daily 
administration of NVBo is feasible and safe at the recom-
mended dose level (30–40 mg/d). PK assessment indicated 
that blood concentrations of vinorelbine after daily admin-
istration are continuously maintained at rather low levels, 
which would have a potential to trigger anti-angiogenic and 
immune-mediated antitumor mechanisms. Further studies are 
warranted to evaluate the efficacy and to further characterize 
the safety of this novel approach.
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